1-8 of 8
Brian Estrella
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Hua-Jay J Cherng, Barbara Pro, Jennifer E. Amengual
Journal: Blood
Blood (2024) 144 (Supplement 1): 336.
https://doi.org/10.1182/blood-2024-203382
Published: 2024
Journal Articles

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Ted B. Piorczynski, Yun Kyoung Ryu, Manuel Pazos, II, Wenxuan Huang, Seda S. Tolu, Brian Estrella, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4391.
https://doi.org/10.1182/blood-2023-179271
Published: 2023
Journal Articles

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Manuel Pazos, II, Brian Estrella, Ted B. Piorczynski, Seda S. Tolu, Wenxuan Huang, Yun Kyoung Ryu, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2023-186639
Published: 2023
Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 6118.
https://doi.org/10.1182/blood-2023-180875
Published: 2023
Journal Articles

First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade

Brian Estrella, Manuel A Pazos, II, Edd C Ricker, Yun Kyoung Ryu, Ted B. Piorczynski, Yuxuan Liu, Seda Tolu, Jennifer E. Amengual
Journal: Blood
Blood (2022) 140 (Supplement 1): 358–359.
https://doi.org/10.1182/blood-2022-166929
Published: 2022
Journal Articles

Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL

Edd C Ricker, Brian Estrella, Manuel A Pazos, II, Jennifer E. Amengual
Journal: Blood
Blood (2021) 138 (Supplement 1): 2410.
https://doi.org/10.1182/blood-2021-153460
Published: 2021
Journal Articles

Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas

Brian Estrella, Yuxuan Liu, Edd C Ricker, Manuel A Pazos, II, Jole Fiorito, Elisa Zuccarello, Elisa Calcagno, Barry Honig, Ottavio Arancio, Jennifer E. Amengual
Journal: Blood
Blood (2021) 138 (Supplement 1): 2254.
https://doi.org/10.1182/blood-2021-151442
Published: 2021
Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4068.
https://doi.org/10.1182/blood-2019-125983
Published: 2019